Cargando…
Fecal microbiota transplantation for irritable bowel syndrome: An intervention for the 21(st) century
Irritable bowel syndrome (IBS) affects about 12% of the global population. Although IBS does not develop into a serious disease or increase mortality, it results in a considerable reduction in the quality of life. The etiology of IBS is not known, but the intestinal microbiota appears to play a pivo...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8192290/ https://www.ncbi.nlm.nih.gov/pubmed/34168399 http://dx.doi.org/10.3748/wjg.v27.i22.2921 |
_version_ | 1783706030953201664 |
---|---|
author | El-Salhy, Magdy Patcharatrakul, Tanisa Gonlachanvit, Sutep |
author_facet | El-Salhy, Magdy Patcharatrakul, Tanisa Gonlachanvit, Sutep |
author_sort | El-Salhy, Magdy |
collection | PubMed |
description | Irritable bowel syndrome (IBS) affects about 12% of the global population. Although IBS does not develop into a serious disease or increase mortality, it results in a considerable reduction in the quality of life. The etiology of IBS is not known, but the intestinal microbiota appears to play a pivotal role in its pathophysiology. There is no effective treatment for IBS, and so the applied treatments clinically focus on symptom relief. Fecal microbiota transplantation (FMT), an old Chinese treatment, has been applied to IBS patients in seven randomized controlled trials (RCTs). Positive effects on IBS symptoms in various degrees were obtained in four of these RCTs, while there was no effect in the remaining three. Across the seven RCTs there were marked differences in the selection processes for the donor and treated patients, the transplant dose, the route of administration, and the methods used to measure how the patients responded to FMT. The present frontier discusses these differences and proposes: (1) criteria for selecting an effective donor (superdonor); (2) selection criteria for patients that are suitable for FMT; (3) the optimal FMT dose; and (4) the route of transplant administration. FMT appears to be safe, with only mild, self-limiting side effects of abdominal pain, cramping, tenderness, diarrhea, and constipation. Although it is early to speculate about the mechanisms underlying the effects of FMT, the available data suggest that changes in the intestinal bacteria accompanied by changes in fermentation patterns and fermentation products (specifically short-chain fatty acids) play an important role in improving the IBS symptoms seen after FMT. FMT appears to be a promising treatment for IBS, but further studies are needed before it can be applied in everyday clinical practice. |
format | Online Article Text |
id | pubmed-8192290 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-81922902021-06-23 Fecal microbiota transplantation for irritable bowel syndrome: An intervention for the 21(st) century El-Salhy, Magdy Patcharatrakul, Tanisa Gonlachanvit, Sutep World J Gastroenterol Frontier Irritable bowel syndrome (IBS) affects about 12% of the global population. Although IBS does not develop into a serious disease or increase mortality, it results in a considerable reduction in the quality of life. The etiology of IBS is not known, but the intestinal microbiota appears to play a pivotal role in its pathophysiology. There is no effective treatment for IBS, and so the applied treatments clinically focus on symptom relief. Fecal microbiota transplantation (FMT), an old Chinese treatment, has been applied to IBS patients in seven randomized controlled trials (RCTs). Positive effects on IBS symptoms in various degrees were obtained in four of these RCTs, while there was no effect in the remaining three. Across the seven RCTs there were marked differences in the selection processes for the donor and treated patients, the transplant dose, the route of administration, and the methods used to measure how the patients responded to FMT. The present frontier discusses these differences and proposes: (1) criteria for selecting an effective donor (superdonor); (2) selection criteria for patients that are suitable for FMT; (3) the optimal FMT dose; and (4) the route of transplant administration. FMT appears to be safe, with only mild, self-limiting side effects of abdominal pain, cramping, tenderness, diarrhea, and constipation. Although it is early to speculate about the mechanisms underlying the effects of FMT, the available data suggest that changes in the intestinal bacteria accompanied by changes in fermentation patterns and fermentation products (specifically short-chain fatty acids) play an important role in improving the IBS symptoms seen after FMT. FMT appears to be a promising treatment for IBS, but further studies are needed before it can be applied in everyday clinical practice. Baishideng Publishing Group Inc 2021-06-14 2021-06-14 /pmc/articles/PMC8192290/ /pubmed/34168399 http://dx.doi.org/10.3748/wjg.v27.i22.2921 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Frontier El-Salhy, Magdy Patcharatrakul, Tanisa Gonlachanvit, Sutep Fecal microbiota transplantation for irritable bowel syndrome: An intervention for the 21(st) century |
title | Fecal microbiota transplantation for irritable bowel syndrome: An intervention for the 21(st) century |
title_full | Fecal microbiota transplantation for irritable bowel syndrome: An intervention for the 21(st) century |
title_fullStr | Fecal microbiota transplantation for irritable bowel syndrome: An intervention for the 21(st) century |
title_full_unstemmed | Fecal microbiota transplantation for irritable bowel syndrome: An intervention for the 21(st) century |
title_short | Fecal microbiota transplantation for irritable bowel syndrome: An intervention for the 21(st) century |
title_sort | fecal microbiota transplantation for irritable bowel syndrome: an intervention for the 21(st) century |
topic | Frontier |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8192290/ https://www.ncbi.nlm.nih.gov/pubmed/34168399 http://dx.doi.org/10.3748/wjg.v27.i22.2921 |
work_keys_str_mv | AT elsalhymagdy fecalmicrobiotatransplantationforirritablebowelsyndromeaninterventionforthe21stcentury AT patcharatrakultanisa fecalmicrobiotatransplantationforirritablebowelsyndromeaninterventionforthe21stcentury AT gonlachanvitsutep fecalmicrobiotatransplantationforirritablebowelsyndromeaninterventionforthe21stcentury |